nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—BRAF—melanoma	0.253	0.844	CbGaD
Dabrafenib—RAF1—Vemurafenib—melanoma	0.22	0.455	CbGbCtD
Dabrafenib—BRAF—Vemurafenib—melanoma	0.184	0.381	CbGbCtD
Dabrafenib—ABCB1—melanoma	0.0468	0.156	CbGaD
Dabrafenib—ABCG2—Vemurafenib—melanoma	0.0209	0.0432	CbGbCtD
Dabrafenib—SLCO1B3—Docetaxel—melanoma	0.0155	0.032	CbGbCtD
Dabrafenib—ABCG2—Dactinomycin—melanoma	0.0139	0.0287	CbGbCtD
Dabrafenib—CYP3A4—Temozolomide—melanoma	0.00823	0.017	CbGbCtD
Dabrafenib—ABCG2—Docetaxel—melanoma	0.00717	0.0148	CbGbCtD
Dabrafenib—ABCB1—Dactinomycin—melanoma	0.005	0.0103	CbGbCtD
Dabrafenib—CYP3A4—Vemurafenib—melanoma	0.00451	0.00933	CbGbCtD
Dabrafenib—ABCB1—Docetaxel—melanoma	0.00258	0.00534	CbGbCtD
Dabrafenib—CYP3A4—Docetaxel—melanoma	0.00155	0.0032	CbGbCtD
Dabrafenib—SLC22A8—optic choroid—melanoma	0.00092	0.157	CbGeAlD
Dabrafenib—RAF1—hair follicle—melanoma	0.000638	0.109	CbGeAlD
Dabrafenib—NEK11—lymph node—melanoma	0.00043	0.0732	CbGeAlD
Dabrafenib—RAF1—neck—melanoma	0.000428	0.073	CbGeAlD
Dabrafenib—SIK1—skin of body—melanoma	0.000348	0.0593	CbGeAlD
Dabrafenib—RAF1—eye—melanoma	0.000319	0.0543	CbGeAlD
Dabrafenib—SIK1—mammalian vulva—melanoma	0.000318	0.0541	CbGeAlD
Dabrafenib—LIMK1—lymph node—melanoma	0.000308	0.0524	CbGeAlD
Dabrafenib—RAF1—skin of body—melanoma	0.000277	0.0472	CbGeAlD
Dabrafenib—RAF1—mammalian vulva—melanoma	0.000253	0.0431	CbGeAlD
Dabrafenib—SIK1—head—melanoma	0.000227	0.0387	CbGeAlD
Dabrafenib—Bone disorder—Docetaxel—melanoma	0.000205	0.00193	CcSEcCtD
Dabrafenib—Oropharyngeal pain—Docetaxel—melanoma	0.000203	0.00191	CcSEcCtD
Dabrafenib—Hyperbilirubinaemia—Docetaxel—melanoma	0.000203	0.00191	CcSEcCtD
Dabrafenib—Arthralgia—Vemurafenib—melanoma	0.000202	0.0019	CcSEcCtD
Dabrafenib—Myalgia—Vemurafenib—melanoma	0.000202	0.0019	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000201	0.00189	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.000201	0.00189	CcSEcCtD
Dabrafenib—Infection—Vemurafenib—melanoma	0.000193	0.00181	CcSEcCtD
Dabrafenib—Nervous system disorder—Vemurafenib—melanoma	0.00019	0.00179	CcSEcCtD
Dabrafenib—BRAF—lymph node—melanoma	0.00019	0.0324	CbGeAlD
Dabrafenib—Hypokalaemia—Carmustine—melanoma	0.00019	0.00179	CcSEcCtD
Dabrafenib—Skin disorder—Vemurafenib—melanoma	0.000188	0.00177	CcSEcCtD
Dabrafenib—Dehydration—Temozolomide—melanoma	0.000188	0.00177	CcSEcCtD
Dabrafenib—SLC22A8—eye—melanoma	0.000185	0.0315	CbGeAlD
Dabrafenib—Dry skin—Temozolomide—melanoma	0.000185	0.00174	CcSEcCtD
Dabrafenib—Phosphatase alkaline increased—Docetaxel—melanoma	0.000185	0.00174	CcSEcCtD
Dabrafenib—Hypokalaemia—Temozolomide—melanoma	0.000184	0.00173	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Temozolomide—melanoma	0.000182	0.00171	CcSEcCtD
Dabrafenib—Hypotension—Vemurafenib—melanoma	0.000181	0.00171	CcSEcCtD
Dabrafenib—RAF1—head—melanoma	0.000181	0.0308	CbGeAlD
Dabrafenib—Neutropenia—Dactinomycin—melanoma	0.00018	0.0017	CcSEcCtD
Dabrafenib—Stomatitis—Bleomycin—melanoma	0.00018	0.00169	CcSEcCtD
Dabrafenib—Influenza like illness—Docetaxel—melanoma	0.000179	0.00169	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Temozolomide—melanoma	0.000178	0.00167	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Vemurafenib—melanoma	0.000177	0.00166	CcSEcCtD
Dabrafenib—Haematuria—Bleomycin—melanoma	0.000176	0.00165	CcSEcCtD
Dabrafenib—Neutropenia—Carmustine—melanoma	0.000169	0.00159	CcSEcCtD
Dabrafenib—Decreased appetite—Vemurafenib—melanoma	0.000169	0.00159	CcSEcCtD
Dabrafenib—Stomatitis—Dactinomycin—melanoma	0.000168	0.00158	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Vemurafenib—melanoma	0.000167	0.00158	CcSEcCtD
Dabrafenib—Fatigue—Vemurafenib—melanoma	0.000167	0.00157	CcSEcCtD
Dabrafenib—Neoplasm—Docetaxel—melanoma	0.000167	0.00157	CcSEcCtD
Dabrafenib—Haemoglobin—Bleomycin—melanoma	0.000166	0.00156	CcSEcCtD
Dabrafenib—Constipation—Vemurafenib—melanoma	0.000166	0.00156	CcSEcCtD
Dabrafenib—Haemorrhage—Bleomycin—melanoma	0.000165	0.00156	CcSEcCtD
Dabrafenib—Neutropenia—Temozolomide—melanoma	0.000163	0.00153	CcSEcCtD
Dabrafenib—Hyperglycaemia—Carmustine—melanoma	0.000163	0.00153	CcSEcCtD
Dabrafenib—SIK1—lymph node—melanoma	0.000159	0.0271	CbGeAlD
Dabrafenib—Renal failure—Carmustine—melanoma	0.000158	0.00149	CcSEcCtD
Dabrafenib—Hyperglycaemia—Temozolomide—melanoma	0.000157	0.00148	CcSEcCtD
Dabrafenib—Stomatitis—Carmustine—melanoma	0.000157	0.00148	CcSEcCtD
Dabrafenib—Urinary tract infection—Carmustine—melanoma	0.000156	0.00147	CcSEcCtD
Dabrafenib—Infestation NOS—Temozolomide—melanoma	0.000155	0.00146	CcSEcCtD
Dabrafenib—Infestation—Temozolomide—melanoma	0.000155	0.00146	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Docetaxel—melanoma	0.000154	0.00145	CcSEcCtD
Dabrafenib—Body temperature increased—Vemurafenib—melanoma	0.000153	0.00144	CcSEcCtD
Dabrafenib—Stomatitis—Temozolomide—melanoma	0.000152	0.00143	CcSEcCtD
Dabrafenib—Urinary tract infection—Temozolomide—melanoma	0.000151	0.00142	CcSEcCtD
Dabrafenib—Chills—Bleomycin—melanoma	0.000148	0.0014	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Docetaxel—melanoma	0.000148	0.00139	CcSEcCtD
Dabrafenib—Alopecia—Bleomycin—melanoma	0.000146	0.00138	CcSEcCtD
Dabrafenib—Haemoglobin—Carmustine—melanoma	0.000145	0.00137	CcSEcCtD
Dabrafenib—Haemorrhage—Carmustine—melanoma	0.000144	0.00136	CcSEcCtD
Dabrafenib—Erythema—Bleomycin—melanoma	0.000144	0.00136	CcSEcCtD
Dabrafenib—Hypersensitivity—Vemurafenib—melanoma	0.000143	0.00135	CcSEcCtD
Dabrafenib—Oedema peripheral—Carmustine—melanoma	0.000142	0.00134	CcSEcCtD
Dabrafenib—Connective tissue disorder—Carmustine—melanoma	0.000142	0.00134	CcSEcCtD
Dabrafenib—Dermatitis bullous—Docetaxel—melanoma	0.00014	0.00132	CcSEcCtD
Dabrafenib—Haemoglobin—Temozolomide—melanoma	0.00014	0.00132	CcSEcCtD
Dabrafenib—Haemorrhage—Temozolomide—melanoma	0.00014	0.00131	CcSEcCtD
Dabrafenib—Asthenia—Vemurafenib—melanoma	0.000139	0.00131	CcSEcCtD
Dabrafenib—Chills—Dactinomycin—melanoma	0.000138	0.0013	CcSEcCtD
Dabrafenib—Urinary tract disorder—Temozolomide—melanoma	0.000138	0.0013	CcSEcCtD
Dabrafenib—Oedema peripheral—Temozolomide—melanoma	0.000137	0.00129	CcSEcCtD
Dabrafenib—Pruritus—Vemurafenib—melanoma	0.000137	0.00129	CcSEcCtD
Dabrafenib—Connective tissue disorder—Temozolomide—melanoma	0.000137	0.00129	CcSEcCtD
Dabrafenib—Urethral disorder—Temozolomide—melanoma	0.000137	0.00129	CcSEcCtD
Dabrafenib—Alopecia—Dactinomycin—melanoma	0.000136	0.00128	CcSEcCtD
Dabrafenib—Eye disorder—Carmustine—melanoma	0.000135	0.00127	CcSEcCtD
Dabrafenib—Hyponatraemia—Docetaxel—melanoma	0.000135	0.00127	CcSEcCtD
Dabrafenib—Erythema—Dactinomycin—melanoma	0.000134	0.00126	CcSEcCtD
Dabrafenib—Pain in extremity—Docetaxel—melanoma	0.000134	0.00126	CcSEcCtD
Dabrafenib—Anaemia—Bleomycin—melanoma	0.000133	0.00125	CcSEcCtD
Dabrafenib—Diarrhoea—Vemurafenib—melanoma	0.000133	0.00125	CcSEcCtD
Dabrafenib—Eye disorder—Temozolomide—melanoma	0.00013	0.00123	CcSEcCtD
Dabrafenib—Arrhythmia—Carmustine—melanoma	0.000129	0.00121	CcSEcCtD
Dabrafenib—Leukopenia—Bleomycin—melanoma	0.000129	0.00121	CcSEcCtD
Dabrafenib—Dizziness—Vemurafenib—melanoma	0.000128	0.00121	CcSEcCtD
Dabrafenib—Alopecia—Carmustine—melanoma	0.000128	0.0012	CcSEcCtD
Dabrafenib—Angiopathy—Temozolomide—melanoma	0.000127	0.00119	CcSEcCtD
Dabrafenib—RAF1—lymph node—melanoma	0.000127	0.0216	CbGeAlD
Dabrafenib—Mental disorder—Carmustine—melanoma	0.000127	0.00119	CcSEcCtD
Dabrafenib—Immune system disorder—Temozolomide—melanoma	0.000126	0.00119	CcSEcCtD
Dabrafenib—Mediastinal disorder—Temozolomide—melanoma	0.000126	0.00118	CcSEcCtD
Dabrafenib—Erythema—Carmustine—melanoma	0.000126	0.00118	CcSEcCtD
Dabrafenib—Malnutrition—Carmustine—melanoma	0.000126	0.00118	CcSEcCtD
Dabrafenib—Cough—Bleomycin—melanoma	0.000126	0.00118	CcSEcCtD
Dabrafenib—Chills—Temozolomide—melanoma	0.000125	0.00118	CcSEcCtD
Dabrafenib—Dehydration—Docetaxel—melanoma	0.000125	0.00117	CcSEcCtD
Dabrafenib—Anaemia—Dactinomycin—melanoma	0.000124	0.00117	CcSEcCtD
Dabrafenib—Vomiting—Vemurafenib—melanoma	0.000123	0.00116	CcSEcCtD
Dabrafenib—Alopecia—Temozolomide—melanoma	0.000123	0.00116	CcSEcCtD
Dabrafenib—Dry skin—Docetaxel—melanoma	0.000123	0.00116	CcSEcCtD
Dabrafenib—Myalgia—Bleomycin—melanoma	0.000123	0.00115	CcSEcCtD
Dabrafenib—Abdominal pain upper—Docetaxel—melanoma	0.000123	0.00115	CcSEcCtD
Dabrafenib—Rash—Vemurafenib—melanoma	0.000122	0.00115	CcSEcCtD
Dabrafenib—Mental disorder—Temozolomide—melanoma	0.000122	0.00115	CcSEcCtD
Dabrafenib—Dermatitis—Vemurafenib—melanoma	0.000122	0.00115	CcSEcCtD
Dabrafenib—ABCB1—blood vessel—melanoma	0.000122	0.0208	CbGeAlD
Dabrafenib—Back pain—Carmustine—melanoma	0.000122	0.00114	CcSEcCtD
Dabrafenib—Headache—Vemurafenib—melanoma	0.000122	0.00114	CcSEcCtD
Dabrafenib—Malnutrition—Temozolomide—melanoma	0.000121	0.00114	CcSEcCtD
Dabrafenib—Erythema—Temozolomide—melanoma	0.000121	0.00114	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000121	0.00114	CcSEcCtD
Dabrafenib—Leukopenia—Dactinomycin—melanoma	0.00012	0.00113	CcSEcCtD
Dabrafenib—Nasopharyngitis—Docetaxel—melanoma	0.00012	0.00113	CcSEcCtD
Dabrafenib—Vision blurred—Carmustine—melanoma	0.000118	0.00112	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Docetaxel—melanoma	0.000118	0.00111	CcSEcCtD
Dabrafenib—Oedema—Bleomycin—melanoma	0.000118	0.00111	CcSEcCtD
Dabrafenib—Back pain—Temozolomide—melanoma	0.000118	0.00111	CcSEcCtD
Dabrafenib—Infection—Bleomycin—melanoma	0.000117	0.0011	CcSEcCtD
Dabrafenib—Anaemia—Carmustine—melanoma	0.000116	0.00109	CcSEcCtD
Dabrafenib—Nausea—Vemurafenib—melanoma	0.000115	0.00108	CcSEcCtD
Dabrafenib—Thrombocytopenia—Bleomycin—melanoma	0.000115	0.00108	CcSEcCtD
Dabrafenib—Vision blurred—Temozolomide—melanoma	0.000114	0.00108	CcSEcCtD
Dabrafenib—Myalgia—Dactinomycin—melanoma	0.000114	0.00108	CcSEcCtD
Dabrafenib—Leukopenia—Carmustine—melanoma	0.000113	0.00106	CcSEcCtD
Dabrafenib—Anaemia—Temozolomide—melanoma	0.000112	0.00106	CcSEcCtD
Dabrafenib—Hypotension—Bleomycin—melanoma	0.00011	0.00103	CcSEcCtD
Dabrafenib—Oedema—Dactinomycin—melanoma	0.00011	0.00103	CcSEcCtD
Dabrafenib—Infection—Dactinomycin—melanoma	0.000109	0.00102	CcSEcCtD
Dabrafenib—Leukopenia—Temozolomide—melanoma	0.000109	0.00102	CcSEcCtD
Dabrafenib—Hypertension—Carmustine—melanoma	0.000109	0.00102	CcSEcCtD
Dabrafenib—Neutropenia—Docetaxel—melanoma	0.000108	0.00102	CcSEcCtD
Dabrafenib—Thrombocytopenia—Dactinomycin—melanoma	0.000107	0.00101	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Bleomycin—melanoma	0.000107	0.00101	CcSEcCtD
Dabrafenib—Myalgia—Carmustine—melanoma	0.000107	0.00101	CcSEcCtD
Dabrafenib—Cough—Temozolomide—melanoma	0.000106	0.000998	CcSEcCtD
Dabrafenib—SLC22A8—head—melanoma	0.000105	0.0179	CbGeAlD
Dabrafenib—Hypertension—Temozolomide—melanoma	0.000105	0.000987	CcSEcCtD
Dabrafenib—ABCG2—mammalian vulva—melanoma	0.000105	0.0178	CbGeAlD
Dabrafenib—Arthralgia—Temozolomide—melanoma	0.000103	0.000973	CcSEcCtD
Dabrafenib—Myalgia—Temozolomide—melanoma	0.000103	0.000973	CcSEcCtD
Dabrafenib—Infestation NOS—Docetaxel—melanoma	0.000103	0.000973	CcSEcCtD
Dabrafenib—Infestation—Docetaxel—melanoma	0.000103	0.000973	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000103	0.000967	CcSEcCtD
Dabrafenib—Oedema—Carmustine—melanoma	0.000103	0.000966	CcSEcCtD
Dabrafenib—Decreased appetite—Bleomycin—melanoma	0.000102	0.000962	CcSEcCtD
Dabrafenib—Infection—Carmustine—melanoma	0.000102	0.000959	CcSEcCtD
Dabrafenib—Renal failure—Docetaxel—melanoma	0.000102	0.000956	CcSEcCtD
Dabrafenib—Dry mouth—Temozolomide—melanoma	0.000101	0.000952	CcSEcCtD
Dabrafenib—Stomatitis—Docetaxel—melanoma	0.000101	0.000948	CcSEcCtD
Dabrafenib—Thrombocytopenia—Carmustine—melanoma	0.0001	0.000945	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Dactinomycin—melanoma	9.99e-05	0.00094	CcSEcCtD
Dabrafenib—Oedema—Temozolomide—melanoma	9.92e-05	0.000933	CcSEcCtD
Dabrafenib—Infection—Temozolomide—melanoma	9.85e-05	0.000927	CcSEcCtD
Dabrafenib—Epistaxis—Docetaxel—melanoma	9.75e-05	0.000918	CcSEcCtD
Dabrafenib—Nervous system disorder—Temozolomide—melanoma	9.72e-05	0.000915	CcSEcCtD
Dabrafenib—Thrombocytopenia—Temozolomide—melanoma	9.71e-05	0.000914	CcSEcCtD
Dabrafenib—Skin disorder—Temozolomide—melanoma	9.63e-05	0.000906	CcSEcCtD
Dabrafenib—Hypotension—Carmustine—melanoma	9.59e-05	0.000902	CcSEcCtD
Dabrafenib—Hyperhidrosis—Temozolomide—melanoma	9.59e-05	0.000902	CcSEcCtD
Dabrafenib—Decreased appetite—Dactinomycin—melanoma	9.53e-05	0.000897	CcSEcCtD
Dabrafenib—Fatigue—Dactinomycin—melanoma	9.45e-05	0.000889	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Carmustine—melanoma	9.35e-05	0.00088	CcSEcCtD
Dabrafenib—Haemoglobin—Docetaxel—melanoma	9.33e-05	0.000878	CcSEcCtD
Dabrafenib—Body temperature increased—Bleomycin—melanoma	9.29e-05	0.000874	CcSEcCtD
Dabrafenib—Haemorrhage—Docetaxel—melanoma	9.28e-05	0.000873	CcSEcCtD
Dabrafenib—Insomnia—Carmustine—melanoma	9.28e-05	0.000873	CcSEcCtD
Dabrafenib—Urinary tract disorder—Docetaxel—melanoma	9.17e-05	0.000863	CcSEcCtD
Dabrafenib—Oedema peripheral—Docetaxel—melanoma	9.14e-05	0.00086	CcSEcCtD
Dabrafenib—Connective tissue disorder—Docetaxel—melanoma	9.12e-05	0.000858	CcSEcCtD
Dabrafenib—Urethral disorder—Docetaxel—melanoma	9.1e-05	0.000856	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Temozolomide—melanoma	9.03e-05	0.00085	CcSEcCtD
Dabrafenib—Insomnia—Temozolomide—melanoma	8.97e-05	0.000844	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dactinomycin—melanoma	8.96e-05	0.000844	CcSEcCtD
Dabrafenib—Decreased appetite—Carmustine—melanoma	8.92e-05	0.000839	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Carmustine—melanoma	8.86e-05	0.000834	CcSEcCtD
Dabrafenib—Constipation—Carmustine—melanoma	8.77e-05	0.000826	CcSEcCtD
Dabrafenib—Eye disorder—Docetaxel—melanoma	8.67e-05	0.000816	CcSEcCtD
Dabrafenib—Abdominal pain—Dactinomycin—melanoma	8.67e-05	0.000816	CcSEcCtD
Dabrafenib—Body temperature increased—Dactinomycin—melanoma	8.67e-05	0.000816	CcSEcCtD
Dabrafenib—Hypersensitivity—Bleomycin—melanoma	8.66e-05	0.000815	CcSEcCtD
Dabrafenib—Decreased appetite—Temozolomide—melanoma	8.62e-05	0.000811	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Temozolomide—melanoma	8.56e-05	0.000806	CcSEcCtD
Dabrafenib—Fatigue—Temozolomide—melanoma	8.55e-05	0.000805	CcSEcCtD
Dabrafenib—Constipation—Temozolomide—melanoma	8.48e-05	0.000798	CcSEcCtD
Dabrafenib—Asthenia—Bleomycin—melanoma	8.43e-05	0.000794	CcSEcCtD
Dabrafenib—Angiopathy—Docetaxel—melanoma	8.42e-05	0.000792	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Carmustine—melanoma	8.39e-05	0.00079	CcSEcCtD
Dabrafenib—Immune system disorder—Docetaxel—melanoma	8.38e-05	0.000789	CcSEcCtD
Dabrafenib—Mediastinal disorder—Docetaxel—melanoma	8.36e-05	0.000787	CcSEcCtD
Dabrafenib—Chills—Docetaxel—melanoma	8.33e-05	0.000784	CcSEcCtD
Dabrafenib—Pruritus—Bleomycin—melanoma	8.32e-05	0.000783	CcSEcCtD
Dabrafenib—Arrhythmia—Docetaxel—melanoma	8.29e-05	0.00078	CcSEcCtD
Dabrafenib—Alopecia—Docetaxel—melanoma	8.2e-05	0.000772	CcSEcCtD
Dabrafenib—Mental disorder—Docetaxel—melanoma	8.13e-05	0.000765	CcSEcCtD
Dabrafenib—Abdominal pain—Carmustine—melanoma	8.11e-05	0.000763	CcSEcCtD
Dabrafenib—Body temperature increased—Carmustine—melanoma	8.11e-05	0.000763	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Temozolomide—melanoma	8.11e-05	0.000763	CcSEcCtD
Dabrafenib—Erythema—Docetaxel—melanoma	8.08e-05	0.00076	CcSEcCtD
Dabrafenib—Malnutrition—Docetaxel—melanoma	8.08e-05	0.00076	CcSEcCtD
Dabrafenib—Hypersensitivity—Dactinomycin—melanoma	8.08e-05	0.00076	CcSEcCtD
Dabrafenib—Asthenia—Dactinomycin—melanoma	7.87e-05	0.00074	CcSEcCtD
Dabrafenib—Abdominal pain—Temozolomide—melanoma	7.84e-05	0.000738	CcSEcCtD
Dabrafenib—Body temperature increased—Temozolomide—melanoma	7.84e-05	0.000738	CcSEcCtD
Dabrafenib—Back pain—Docetaxel—melanoma	7.81e-05	0.000735	CcSEcCtD
Dabrafenib—Muscle spasms—Docetaxel—melanoma	7.77e-05	0.000731	CcSEcCtD
Dabrafenib—Hypersensitivity—Carmustine—melanoma	7.56e-05	0.000711	CcSEcCtD
Dabrafenib—Diarrhoea—Dactinomycin—melanoma	7.5e-05	0.000706	CcSEcCtD
Dabrafenib—Vomiting—Bleomycin—melanoma	7.47e-05	0.000703	CcSEcCtD
Dabrafenib—Anaemia—Docetaxel—melanoma	7.47e-05	0.000703	CcSEcCtD
Dabrafenib—Rash—Bleomycin—melanoma	7.41e-05	0.000697	CcSEcCtD
Dabrafenib—Dermatitis—Bleomycin—melanoma	7.4e-05	0.000697	CcSEcCtD
Dabrafenib—Asthenia—Carmustine—melanoma	7.36e-05	0.000693	CcSEcCtD
Dabrafenib—Hypersensitivity—Temozolomide—melanoma	7.31e-05	0.000687	CcSEcCtD
Dabrafenib—Leukopenia—Docetaxel—melanoma	7.23e-05	0.000681	CcSEcCtD
Dabrafenib—Asthenia—Temozolomide—melanoma	7.11e-05	0.000669	CcSEcCtD
Dabrafenib—Cough—Docetaxel—melanoma	7.05e-05	0.000663	CcSEcCtD
Dabrafenib—Diarrhoea—Carmustine—melanoma	7.02e-05	0.000661	CcSEcCtD
Dabrafenib—Pruritus—Temozolomide—melanoma	7.01e-05	0.00066	CcSEcCtD
Dabrafenib—Nausea—Bleomycin—melanoma	6.98e-05	0.000657	CcSEcCtD
Dabrafenib—Hypertension—Docetaxel—melanoma	6.98e-05	0.000656	CcSEcCtD
Dabrafenib—Vomiting—Dactinomycin—melanoma	6.97e-05	0.000656	CcSEcCtD
Dabrafenib—Rash—Dactinomycin—melanoma	6.91e-05	0.00065	CcSEcCtD
Dabrafenib—Myalgia—Docetaxel—melanoma	6.88e-05	0.000647	CcSEcCtD
Dabrafenib—Arthralgia—Docetaxel—melanoma	6.88e-05	0.000647	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	6.83e-05	0.000643	CcSEcCtD
Dabrafenib—Dizziness—Carmustine—melanoma	6.78e-05	0.000639	CcSEcCtD
Dabrafenib—Diarrhoea—Temozolomide—melanoma	6.78e-05	0.000638	CcSEcCtD
Dabrafenib—Dry mouth—Docetaxel—melanoma	6.73e-05	0.000633	CcSEcCtD
Dabrafenib—Oedema—Docetaxel—melanoma	6.59e-05	0.000621	CcSEcCtD
Dabrafenib—Dizziness—Temozolomide—melanoma	6.56e-05	0.000617	CcSEcCtD
Dabrafenib—Infection—Docetaxel—melanoma	6.55e-05	0.000616	CcSEcCtD
Dabrafenib—Vomiting—Carmustine—melanoma	6.52e-05	0.000614	CcSEcCtD
Dabrafenib—Nausea—Dactinomycin—melanoma	6.51e-05	0.000613	CcSEcCtD
Dabrafenib—Rash—Carmustine—melanoma	6.47e-05	0.000609	CcSEcCtD
Dabrafenib—Nervous system disorder—Docetaxel—melanoma	6.47e-05	0.000609	CcSEcCtD
Dabrafenib—Dermatitis—Carmustine—melanoma	6.46e-05	0.000608	CcSEcCtD
Dabrafenib—Thrombocytopenia—Docetaxel—melanoma	6.46e-05	0.000608	CcSEcCtD
Dabrafenib—ABCB1—retina—melanoma	6.44e-05	0.011	CbGeAlD
Dabrafenib—Headache—Carmustine—melanoma	6.43e-05	0.000605	CcSEcCtD
Dabrafenib—Skin disorder—Docetaxel—melanoma	6.4e-05	0.000603	CcSEcCtD
Dabrafenib—Vomiting—Temozolomide—melanoma	6.3e-05	0.000593	CcSEcCtD
Dabrafenib—Rash—Temozolomide—melanoma	6.25e-05	0.000588	CcSEcCtD
Dabrafenib—Dermatitis—Temozolomide—melanoma	6.25e-05	0.000588	CcSEcCtD
Dabrafenib—Headache—Temozolomide—melanoma	6.21e-05	0.000585	CcSEcCtD
Dabrafenib—Hypotension—Docetaxel—melanoma	6.16e-05	0.00058	CcSEcCtD
Dabrafenib—Nausea—Carmustine—melanoma	6.09e-05	0.000574	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Docetaxel—melanoma	6.01e-05	0.000565	CcSEcCtD
Dabrafenib—Insomnia—Docetaxel—melanoma	5.96e-05	0.000561	CcSEcCtD
Dabrafenib—Nausea—Temozolomide—melanoma	5.89e-05	0.000554	CcSEcCtD
Dabrafenib—Decreased appetite—Docetaxel—melanoma	5.73e-05	0.000539	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Docetaxel—melanoma	5.69e-05	0.000536	CcSEcCtD
Dabrafenib—Fatigue—Docetaxel—melanoma	5.68e-05	0.000535	CcSEcCtD
Dabrafenib—Constipation—Docetaxel—melanoma	5.64e-05	0.000531	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Docetaxel—melanoma	5.39e-05	0.000507	CcSEcCtD
Dabrafenib—ABCG2—lymph node—melanoma	5.24e-05	0.00892	CbGeAlD
Dabrafenib—Body temperature increased—Docetaxel—melanoma	5.21e-05	0.000491	CcSEcCtD
Dabrafenib—Abdominal pain—Docetaxel—melanoma	5.21e-05	0.000491	CcSEcCtD
Dabrafenib—ABCB1—mammalian vulva—melanoma	5.15e-05	0.00878	CbGeAlD
Dabrafenib—Hypersensitivity—Docetaxel—melanoma	4.86e-05	0.000457	CcSEcCtD
Dabrafenib—Asthenia—Docetaxel—melanoma	4.73e-05	0.000445	CcSEcCtD
Dabrafenib—Pruritus—Docetaxel—melanoma	4.67e-05	0.000439	CcSEcCtD
Dabrafenib—Diarrhoea—Docetaxel—melanoma	4.51e-05	0.000425	CcSEcCtD
Dabrafenib—Dizziness—Docetaxel—melanoma	4.36e-05	0.00041	CcSEcCtD
Dabrafenib—Vomiting—Docetaxel—melanoma	4.19e-05	0.000395	CcSEcCtD
Dabrafenib—Rash—Docetaxel—melanoma	4.16e-05	0.000391	CcSEcCtD
Dabrafenib—Dermatitis—Docetaxel—melanoma	4.15e-05	0.000391	CcSEcCtD
Dabrafenib—Headache—Docetaxel—melanoma	4.13e-05	0.000389	CcSEcCtD
Dabrafenib—Nausea—Docetaxel—melanoma	3.92e-05	0.000369	CcSEcCtD
Dabrafenib—ABCB1—head—melanoma	3.69e-05	0.00628	CbGeAlD
Dabrafenib—ABCB1—lymph node—melanoma	2.58e-05	0.0044	CbGeAlD
Dabrafenib—SLCO1B3—Metabolism—PIK3CB—melanoma	2.49e-06	2.38e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAP2K1—melanoma	2.48e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.48e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ITGB3—melanoma	2.48e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PRKCA—melanoma	2.48e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—HRAS—melanoma	2.47e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—melanoma	2.47e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CD—melanoma	2.47e-06	2.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAP2K1—melanoma	2.45e-06	2.34e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—melanoma	2.45e-06	2.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CD—melanoma	2.44e-06	2.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SPP1—melanoma	2.43e-06	2.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAP2K2—melanoma	2.42e-06	2.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL8—melanoma	2.42e-06	2.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—melanoma	2.41e-06	2.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PIK3CA—melanoma	2.41e-06	2.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—BCL2—melanoma	2.4e-06	2.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNG—melanoma	2.38e-06	2.27e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GNA11—melanoma	2.37e-06	2.27e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—STAT3—melanoma	2.37e-06	2.26e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NRAS—melanoma	2.37e-06	2.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MDM2—melanoma	2.36e-06	2.26e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGF2—melanoma	2.36e-06	2.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGF2—melanoma	2.33e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ERBB2—melanoma	2.33e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PHGDH—melanoma	2.33e-06	2.22e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LUM—melanoma	2.33e-06	2.22e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—FASN—melanoma	2.32e-06	2.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—melanoma	2.31e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PIK3CA—melanoma	2.31e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TERT—melanoma	2.3e-06	2.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CB—melanoma	2.3e-06	2.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RAC1—melanoma	2.3e-06	2.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—melanoma	2.3e-06	2.19e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.29e-06	2.19e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC5A5—melanoma	2.29e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HPSE—melanoma	2.28e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MAPK3—melanoma	2.27e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	2.25e-06	2.14e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CUBN—melanoma	2.24e-06	2.14e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—melanoma	2.23e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—melanoma	2.23e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MDM2—melanoma	2.21e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GNAQ—melanoma	2.21e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CD44—melanoma	2.21e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—melanoma	2.2e-06	2.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HIF1A—melanoma	2.2e-06	2.1e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP17A1—melanoma	2.19e-06	2.09e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CG—melanoma	2.19e-06	2.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—melanoma	2.18e-06	2.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MDM2—melanoma	2.18e-06	2.08e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ERBB2—melanoma	2.18e-06	2.08e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SDHD—melanoma	2.16e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BSG—melanoma	2.16e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CSPG4—melanoma	2.16e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.16e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1B—melanoma	2.16e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MAPK1—melanoma	2.16e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—melanoma	2.16e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTEN—melanoma	2.15e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERBB2—melanoma	2.15e-06	2.05e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CB—melanoma	2.15e-06	2.05e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.14e-06	2.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—melanoma	2.14e-06	2.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—melanoma	2.13e-06	2.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CB—melanoma	2.12e-06	2.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—melanoma	2.12e-06	2.02e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP1B1—melanoma	2.12e-06	2.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—melanoma	2.11e-06	2.02e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—melanoma	2.11e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KDR—melanoma	2.11e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—melanoma	2.1e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPAM—melanoma	2.09e-06	2e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GNA11—melanoma	2.07e-06	1.98e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—melanoma	2.07e-06	1.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTNNB1—melanoma	2.04e-06	1.95e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—melanoma	2.04e-06	1.94e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	2.03e-06	1.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FN1—melanoma	2.03e-06	1.94e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—FASN—melanoma	2.02e-06	1.93e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CG—melanoma	2.02e-06	1.93e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1B—melanoma	2.02e-06	1.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1B—melanoma	1.99e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1A—melanoma	1.99e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC5A5—melanoma	1.99e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTEN—melanoma	1.99e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH1—melanoma	1.98e-06	1.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NFKB1—melanoma	1.98e-06	1.89e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—melanoma	1.98e-06	1.89e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—melanoma	1.97e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—melanoma	1.97e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—melanoma	1.95e-06	1.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CD80—melanoma	1.94e-06	1.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CG—melanoma	1.94e-06	1.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APC—melanoma	1.94e-06	1.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIT—melanoma	1.94e-06	1.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—NRAS—melanoma	1.94e-06	1.85e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—melanoma	1.92e-06	1.84e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GNAQ—melanoma	1.92e-06	1.84e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CD44—melanoma	1.92e-06	1.84e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CD—melanoma	1.92e-06	1.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGF—melanoma	1.92e-06	1.83e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CTNNB1—melanoma	1.91e-06	1.82e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—melanoma	1.9e-06	1.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—melanoma	1.89e-06	1.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CTNNB1—melanoma	1.88e-06	1.8e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—melanoma	1.87e-06	1.79e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—melanoma	1.87e-06	1.78e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.87e-06	1.78e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1A—melanoma	1.86e-06	1.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—MAPK3—melanoma	1.86e-06	1.77e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTEN—melanoma	1.86e-06	1.77e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NFKB1—melanoma	1.85e-06	1.76e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1B1—melanoma	1.84e-06	1.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1A—melanoma	1.84e-06	1.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTEN—melanoma	1.84e-06	1.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BRAF—melanoma	1.82e-06	1.74e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLA2G6—melanoma	1.78e-06	1.7e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CD—melanoma	1.78e-06	1.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—melanoma	1.78e-06	1.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1—melanoma	1.78e-06	1.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NRAS—melanoma	1.77e-06	1.69e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—MAPK1—melanoma	1.77e-06	1.69e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—melanoma	1.77e-06	1.69e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—melanoma	1.76e-06	1.68e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCB1—melanoma	1.74e-06	1.66e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—melanoma	1.73e-06	1.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAP2K1—melanoma	1.72e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CD—melanoma	1.71e-06	1.63e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK3—melanoma	1.7e-06	1.62e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—melanoma	1.68e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CB—melanoma	1.68e-06	1.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—melanoma	1.67e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—melanoma	1.66e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—melanoma	1.66e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NRAS—melanoma	1.66e-06	1.58e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—melanoma	1.66e-06	1.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—melanoma	1.64e-06	1.57e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NRAS—melanoma	1.64e-06	1.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF2—melanoma	1.63e-06	1.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK1—melanoma	1.62e-06	1.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—melanoma	1.62e-06	1.54e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PRKCA—melanoma	1.6e-06	1.53e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—VCAN—melanoma	1.6e-06	1.53e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ERCC2—melanoma	1.59e-06	1.52e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK3—melanoma	1.59e-06	1.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAPK3—melanoma	1.57e-06	1.5e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CB—melanoma	1.55e-06	1.48e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—melanoma	1.54e-06	1.47e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—melanoma	1.54e-06	1.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—melanoma	1.53e-06	1.47e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—melanoma	1.53e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MDM2—melanoma	1.53e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—melanoma	1.53e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—melanoma	1.52e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—melanoma	1.52e-06	1.45e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK1—melanoma	1.51e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—melanoma	1.51e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB2—melanoma	1.51e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAPK1—melanoma	1.49e-06	1.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—melanoma	1.49e-06	1.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CB—melanoma	1.49e-06	1.42e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTEN—melanoma	1.45e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—melanoma	1.43e-06	1.36e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—melanoma	1.43e-06	1.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—melanoma	1.42e-06	1.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—melanoma	1.41e-06	1.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—melanoma	1.4e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PRKCA—melanoma	1.4e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1B—melanoma	1.4e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ERCC2—melanoma	1.39e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—melanoma	1.37e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—melanoma	1.37e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—melanoma	1.36e-06	1.3e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP17A1—melanoma	1.35e-06	1.29e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTEN—melanoma	1.34e-06	1.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—melanoma	1.33e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNB1—melanoma	1.32e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.32e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—melanoma	1.31e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—melanoma	1.3e-06	1.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—melanoma	1.29e-06	1.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—melanoma	1.29e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1A—melanoma	1.29e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTEN—melanoma	1.29e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NFKB1—melanoma	1.28e-06	1.22e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GNA11—melanoma	1.27e-06	1.22e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—melanoma	1.27e-06	1.21e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CG—melanoma	1.26e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—melanoma	1.25e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—FASN—melanoma	1.25e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—melanoma	1.24e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—melanoma	1.24e-06	1.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC5A5—melanoma	1.23e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—melanoma	1.21e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—melanoma	1.21e-06	1.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—melanoma	1.2e-06	1.14e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GNAQ—melanoma	1.18e-06	1.13e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CD44—melanoma	1.18e-06	1.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—melanoma	1.16e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—melanoma	1.16e-06	1.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—melanoma	1.15e-06	1.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NRAS—melanoma	1.15e-06	1.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—melanoma	1.15e-06	1.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—melanoma	1.15e-06	1.09e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1B1—melanoma	1.14e-06	1.08e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CD—melanoma	1.1e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK3—melanoma	1.1e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CG—melanoma	1.09e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—melanoma	1.09e-06	1.04e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—melanoma	1.07e-06	1.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—melanoma	1.07e-06	1.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—melanoma	1.06e-06	1.01e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—melanoma	1.06e-06	1.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK1—melanoma	1.04e-06	9.98e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—melanoma	1.04e-06	9.97e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—melanoma	1.02e-06	9.75e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—melanoma	9.87e-07	9.42e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CB—melanoma	9.63e-07	9.19e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CD—melanoma	9.62e-07	9.19e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—melanoma	9.54e-07	9.11e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—melanoma	9.5e-07	9.07e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—melanoma	9.46e-07	9.03e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCB1—melanoma	9.35e-07	8.93e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—melanoma	9.07e-07	8.66e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—melanoma	8.77e-07	8.37e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PRKCA—melanoma	8.61e-07	8.22e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ERCC2—melanoma	8.54e-07	8.15e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—melanoma	8.39e-07	8.01e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CB—melanoma	8.39e-07	8.01e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—melanoma	8.34e-07	7.97e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTEN—melanoma	8.32e-07	7.94e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—melanoma	8.31e-07	7.93e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—melanoma	8.03e-07	7.66e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—melanoma	7.73e-07	7.38e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—melanoma	7.41e-07	7.07e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTEN—melanoma	7.25e-07	6.92e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CG—melanoma	6.74e-07	6.44e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—melanoma	6.51e-07	6.21e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CD—melanoma	5.93e-07	5.66e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—melanoma	5.87e-07	5.6e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—melanoma	5.85e-07	5.59e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CB—melanoma	5.17e-07	4.93e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—melanoma	5.12e-07	4.89e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—melanoma	5.11e-07	4.88e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—melanoma	4.79e-07	4.58e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTEN—melanoma	4.47e-07	4.26e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—melanoma	4.18e-07	3.99e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—melanoma	3.15e-07	3.01e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—melanoma	2.57e-07	2.46e-06	CbGpPWpGaD
